Why the study?
Does angiotensin receptor neprilysin inhibition (ARNI) improve clinical symptoms and reduce readmission in patients with heart failure?
Does angiotensin receptor neprilysin inhibition (ARNI) improve clinical symptoms and reduce readmission in patients with heart failure?
Answers are grounded in this paper and cite their sources.
In a real-world retrospective cohort, ARNI therapy improved symptoms and reduced readmissions in heart failure patients, though age >65 and HFrEF remained independent predictors of readmission.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: